Meeting News Coverage

Healio.com to provide live coverage of International Liver Congress 2015

Healio.com/Hepatology will offer live coverage from the International Liver Congress beginning Thursday.

The conference, held April 22 to April 26 in Vienna, Austria, is in its 50th year and will feature experts speaking on critical topics within hepatology. More than 10,800 hepatologists and health care professionals from around the world attended the ILC 2014, according to the ILC website, and more are expected to attend this year to hear the latest research related to hepatitis C virus infection, drug-induced liver injury, nonalcoholic fatty liver disease and more.

“These are very exciting times for Hepatology and for our society in particular,” Markus Peck-Radosavljevic, MD, EASL secretary-general, said in a welcome message on the EASL website. “EASL was founded almost 50 years ago as a society to promote and exchange science in the field of liver diseases. Still today, this remains the most important task for our association. We are happy to witness the exciting data presented at The International Liver Congress and to be published in the Journal of Hepatology, which recently surpassed an impact factor of 10 and consequently ranks as one of the two premier Journals in the field of liver disease.”

Markus Peck-Radosavljevic

In addition to the State-of-the-Art Lectures, abstracts and presentations covering all topics of Hepatology, EASL is launching The Liver Works campaign, an initiative aimed at providing information about the science of the liver and liver diseases, according to the ILC website.

HCV Next Editorial Board members will be in attendance including: Ira M. Jacobson, MD, who will be presenting phase 2 results from the C-SALT (part A) trial; Paul Pockros, MD, who will be presenting a late breaking abstract of results from the RUBY-I Study; and David L. Wyles, MD, who will be presenting results from a study focused on the persistence of resistance-associated variants in patients who did not achieve SVR after receiving ledipasvir without sofosbuvir. – by Melinda Stevens

Visit Healio.com/Hepatology to read the latest news from the meeting, and follow our live updates on Twitter at @HealioHep.

Healio.com/Hepatology will offer live coverage from the International Liver Congress beginning Thursday.

The conference, held April 22 to April 26 in Vienna, Austria, is in its 50th year and will feature experts speaking on critical topics within hepatology. More than 10,800 hepatologists and health care professionals from around the world attended the ILC 2014, according to the ILC website, and more are expected to attend this year to hear the latest research related to hepatitis C virus infection, drug-induced liver injury, nonalcoholic fatty liver disease and more.

“These are very exciting times for Hepatology and for our society in particular,” Markus Peck-Radosavljevic, MD, EASL secretary-general, said in a welcome message on the EASL website. “EASL was founded almost 50 years ago as a society to promote and exchange science in the field of liver diseases. Still today, this remains the most important task for our association. We are happy to witness the exciting data presented at The International Liver Congress and to be published in the Journal of Hepatology, which recently surpassed an impact factor of 10 and consequently ranks as one of the two premier Journals in the field of liver disease.”

Markus Peck-Radosavljevic

In addition to the State-of-the-Art Lectures, abstracts and presentations covering all topics of Hepatology, EASL is launching The Liver Works campaign, an initiative aimed at providing information about the science of the liver and liver diseases, according to the ILC website.

HCV Next Editorial Board members will be in attendance including: Ira M. Jacobson, MD, who will be presenting phase 2 results from the C-SALT (part A) trial; Paul Pockros, MD, who will be presenting a late breaking abstract of results from the RUBY-I Study; and David L. Wyles, MD, who will be presenting results from a study focused on the persistence of resistance-associated variants in patients who did not achieve SVR after receiving ledipasvir without sofosbuvir. – by Melinda Stevens

Visit Healio.com/Hepatology to read the latest news from the meeting, and follow our live updates on Twitter at @HealioHep.

    See more from International Liver Congress